Intrauterine and Neonatal Exposure to Opioids: Toxicological, Clinical, and Medico-Legal Issues.
Giuseppe Davide AlbanoCorinne La SpinaWalter PitingaroVanessa MilazzoValentina TrioloAntonella ArgoGinevra MaltaStefania ZerboPublished in: Toxics (2023)
Opioids have a rapid transplacental passage (i.e., less than 60 min); furthermore, symptoms characterize the maternal and fetal withdrawal syndrome. Opioid withdrawal significantly impacts the fetus, inducing worse outcomes and a risk of mortality. Moreover, neonatal abstinence syndrome (NAS) follows the delivery, lasts up to 10 weeks, and requires intensive management. Therefore, the prevention and adequate management of NAS are relevant public health issues. This review aims to summarize the most updated evidence in the literature regarding toxicological, clinical, and forensic issues of intrauterine exposure to opioids to provide a multidisciplinary, evidence-based approach for managing such issues. Further research is required to standardize testing and to better understand the distribution of opioid derivatives in each specimen type, as well as the clinically relevant cutoff concentrations in quantitative testing results. A multidisciplinary approach is required, with obstetricians, pediatricians, nurses, forensic doctors and toxicologists, social workers, addiction specialists, and politicians all working together to implement social welfare and social services for the baby when needed. The healthcare system should encourage multidisciplinary activity in this field and direct suspected maternal and neonatal opioid intoxication cases to local referral centers.
Keyphrases
- chronic pain
- pain management
- healthcare
- mental health
- public health
- primary care
- birth weight
- case report
- quality improvement
- systematic review
- pregnancy outcomes
- cardiovascular events
- gestational age
- type diabetes
- coronary artery disease
- metabolic syndrome
- insulin resistance
- skeletal muscle
- weight loss
- quantum dots
- sensitive detection